Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
Spinner S, Crispatzu G, Yi JH, Munkhbaatar E, Mayer P, Höckendorf U, Müller N, Li Z, Schader T, Bendz H, Hartmann S, Yabal M, Pechloff K, Heikenwalder M, Kelly GL, Strasser A, Peschel C, Hansmann ML, Ruland J, Keller U, Newrzela S, Herling M, Jost PJ. Spinner S, et al. Among authors: mayer p. Leukemia. 2016 Jul;30(7):1520-30. doi: 10.1038/leu.2016.49. Epub 2016 Mar 8. Leukemia. 2016. PMID: 27055871
CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.
Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L, Breuer A, Crispatzu G, Rosen N, Landwehr T, Lilienthal N, Möllmann M, Montesinos-Rongen M, Heukamp L, Dürig J, Hallek M, Fingerle-Rowson G, Herling M. Fedorchenko O, et al. Among authors: mayer p. Blood. 2013 May 16;121(20):4126-36. doi: 10.1182/blood-2012-11-466250. Epub 2013 Apr 1. Blood. 2013. PMID: 23547049 Free article.
Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek M, Schmalz HG, Prokop A, Mougiakakos D, Herling M. Prinz C, et al. Among authors: mayer p. Mol Cancer. 2015 Jun 4;14:114. doi: 10.1186/s12943-015-0378-1. Mol Cancer. 2015. PMID: 26041471 Free PMC article.
A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells.
Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M. Lilienthal N, et al. Among authors: mayer p. Mol Cancer Ther. 2016 May;15(5):971-84. doi: 10.1158/1535-7163.MCT-15-0685. Epub 2016 Jan 29. Mol Cancer Ther. 2016. PMID: 26826117
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M. Lohmann G, et al. Among authors: mayer p. Leukemia. 2017 May;31(5):1177-1186. doi: 10.1038/leu.2016.294. Epub 2016 Oct 24. Leukemia. 2017. PMID: 27773933
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M. Schrader A, et al. Among authors: mayer p. Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6. Nat Commun. 2018. PMID: 29449575 Free PMC article.
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G. Pflug N, et al. Among authors: mayer p. Leuk Lymphoma. 2019 Mar;60(3):649-657. doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20. Leuk Lymphoma. 2019. PMID: 30234404 Clinical Trial.
Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric Vβ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases.
Kotrova M, Novakova M, Oberbeck S, Mayer P, Schrader A, Knecht H, Hrusak O, Herling M, Brüggemann M. Kotrova M, et al. Among authors: mayer p. Cytometry A. 2018 Nov;93(11):1118-1124. doi: 10.1002/cyto.a.23604. Epub 2018 Nov 10. Cytometry A. 2018. PMID: 30414304 Free article.
1,253 results